{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:08:45Z","timestamp":1790968125325,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ygyno.2020.01.008","type":"journal-article","created":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:52:51Z","timestamp":1578617571000},"page":"252-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Histopathological characterization of ProMisE molecular groups of endometrial cancer"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5443-2333","authenticated-orcid":false,"given":"Antonio","family":"Raffone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-1618","authenticated-orcid":false,"given":"Antonio","family":"Travaglino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Mascolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consolata","family":"Carotenuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Guida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Insabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.01.008_bb0005","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0010","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2019.08.019","article-title":"TCGA molecular groups of endometrial cancer: pooled data about prognosis","author":"Raffone","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0025","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/PAS.0b013e31828c63ed","article-title":"Histotype-genotype correlation in 36 high-grade endometrial carcinomas","volume":"37","author":"Hoang","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0040","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2019.03.098","article-title":"Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma","volume":"153","author":"Britton","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0050","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41379-018-0080-0","article-title":"Nuclear \u03b2-catenin localization and mutation of the CTNNB1 gene: a context-dependent association","volume":"31","author":"Kim","year":"2018","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/aogs.13452","article-title":"Loss of B-cell lymphoma 2 immunohistochemical expression in endometrial hyperplasia: a specific marker of precancer and novel indication for treatment: a systematic review and meta-analysis","volume":"97","author":"Travaglino","year":"2018","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejogrb.2018.10.025","article-title":"PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis","volume":"231","author":"Travaglino","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/aogs.13512","article-title":"PAX2 in endometrial carcinogenesis and in differential diagnosis of endometrial hyperplasia. A systematic review and meta-analysis of diagnostic accuracy","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/aogs.13513","article-title":"Loss of PTEN expression as diagnostic marker of endometrial precancer: a systematic review and meta-analysis","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0075","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajcp\/aqy178","article-title":"Immunohistochemical nuclear expression of \u03b2-catenin as a surrogate of CTNNB1 exon 3 mutation in endometrial cancer","volume":"151","author":"Travaglino","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0080","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/aogs.13586","article-title":"Should progesterone and estrogens receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0085","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/aogs.13587","article-title":"Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review","volume":"98","author":"Travaglino","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0090","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/apm.12938","article-title":"PTEN immunohistochemistry in endometrial hyperplasia: which are the optimal criteria for the diagnosis of precancer?","volume":"127","author":"Travaglino","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0095","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/modpathol.2015.43","article-title":"Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative","volume":"28","author":"Stelloo","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0105","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00404-019-05123-x","article-title":"PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis","volume":"299","author":"Raffone","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/apm.12977","article-title":"Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer","volume":"127","author":"Raffone","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1111\/apm.12988","article-title":"Nuclear expression of \u03b2-catenin in endometrial hyperplasia as marker of premalignancy","author":"Travaglino","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0120","article-title":"Clear cell endometrial carcinoma and the TCGA classification","author":"Travaglino","year":"2019","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.ygyno.2020.01.008_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Systematic Reviews"},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2020.01.008_bb0130","doi-asserted-by":"crossref","first-page":"vi33","DOI":"10.1093\/annonc\/mdt353","article-title":"Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Colombo","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0135","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a newinstrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/his.13776","article-title":"Endometrial hyperplasia and risk of coexistent cancer: WHO vs EIN criteria","volume":"74","author":"Travaglino","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0145","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00404-019-05103-1","article-title":"Endometrial hyperplasia and progression to cancer: which classification system stratifies the risk better? A systematic review and meta-analysis","volume":"299","author":"Raffone","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/aogs.13553","article-title":"Management of women with atypical polypoid adenomyoma of the uterus: a quantitative systematic review","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/apm.12945","article-title":"Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia","volume":"127","author":"Travaglino","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0160","article-title":"Congruence between 1994 WHO classification of endometrial hyperplasia and endometrial intraepithelial neoplasia system","author":"Travaglino","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0165","article-title":"Accuracy of one-step nucleic acid amplification in detecting lymph node metastases in endometrial cancer","author":"Raffone","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0170","first-page":"1","article-title":"Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment","volume":"5","author":"Raffone","year":"2019","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0175","article-title":"Diabetes mellitus is associated with occult cancer in endometrial hyperplasia","author":"Raffone","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.ygyno.2020.01.008_bb0180","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0185","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2019.03.100","article-title":"Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers","volume":"153","author":"Moroney","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"issue":"25","key":"10.1016\/j.ygyno.2020.01.008_bb0195","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.2016.67.8722","article-title":"Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology\/Gynecologic Oncology Group Study","volume":"34","author":"McMeekin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0200","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1097\/AOG.0b013e3182167973","article-title":"Comparative performance of the 2009 International Federation of Gynecology And Obstetrics\u2019 Staging System for uterine corpus cancer","volume":"117","author":"Lewin","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0205","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ygyno.2018.07.020","article-title":"Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: evaluation of the pilot phase of the PORTEC-4a trial","volume":"151","author":"Wortman","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/CCO.0000000000000560","article-title":"Reclassifying endometrial carcinomas with a combined morphological and molecular approach","volume":"31","author":"Carlson","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ygyno.2020.01.008_bb0215","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41379-018-0055-1","article-title":"Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative","volume":"31","author":"Auguste","year":"2018","journal-title":"Mod. Pathol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820300081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:51:58Z","timestamp":1758772318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820300081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0090825820300081"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histopathological characterization of ProMisE molecular groups of endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}